Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2024-02-09 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding the availability of an audio recording of an earnings call held on February 9, 2024, for the quarter and nine months ended December 31, 2023. It provides a link to the recording but does not contain the transcript or detailed financial data itself. The document is only 1083 characters long and serves as an announcement of the earnings call recording, not the call transcript itself. According to the classification rules, a document that announces or provides a link to a call recording without the full transcript should be classified as Regulatory Filings (RNS) because it does not contain the full transcript text required for a Call Transcript (CT).
2024-02-09 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding an update on the company's credit rating by India Ratings and Research. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations. The content is an announcement of a credit rating upgrade, which is a financing-related update. The document is short (1138 characters) and does not contain financial statements or detailed financial data. It is not an earnings release or a full financial report but an update on credit rating, which falls under capital/financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-02-08 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is a detailed presentation addressed to stock exchanges and investors, explicitly titled "Investors/Analysts Presentation" and covering financial results for the quarter and nine months ended December 31, 2023. It includes extensive financial highlights, management commentary, business strategy, operational metrics, and company overview. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events including investor presentations. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal report like an annual or quarterly report. The length (15,000 characters) and detailed financial data support that this is a full presentation document, not a brief announcement or certification. Therefore, the appropriate classification is Investor Presentation (IP).
2024-02-08 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the third quarter and nine months ended December 31, 2023. It includes key financial highlights such as total income, EBITDA, PAT, and EPS, with year-over-year and quarter-over-quarter growth percentages. The document also mentions an upcoming earnings call to discuss these results. The content is typical of an Earnings Release, which provides initial announcement of quarterly financial results with key highlights. The document is about 4988 characters, which is consistent with a press release length rather than a full detailed quarterly report. Therefore, the appropriate classification is Earnings Release (ER). Q3 2024
2024-02-08 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed communication from Neuland Laboratories Limited dated February 8, 2024, addressed to stock exchanges, reporting the outcome of a Board Meeting where unaudited financial results for the quarter and nine months ended December 31, 2023, were approved. It includes the unaudited standalone and consolidated financial results, accompanied by limited review reports from the statutory auditors. The document references compliance with SEBI Listing Regulations and Indian Accounting Standard 34 (Ind AS 34) for interim financial reporting. The presence of detailed financial data for a period shorter than a full fiscal year (quarter and nine months), along with auditor review reports, indicates this is an Interim / Quarterly Report. It is not a full Annual Report (10-K), nor just an announcement or certification. The document length (15,000 characters) and content confirm it is a substantive financial report for an interim period. 9M 2024
2024-02-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges announcing the schedule for the Q3 FY 2024 earnings call and the date of the results announcement. It references the upcoming earnings release and provides details for the earnings call but does not contain any actual financial results or substantive financial data. The document length is 2747 characters, which is relatively short and primarily serves as a notice or announcement. According to the rules, such documents announcing earnings calls and results release dates without the actual financial data should be classified as Earnings Release (ER) if they contain key highlights or initial financial results, but since this document only announces the schedule and call details without any financial results, it fits best as a Regulatory Filing (RNS) or possibly an Earnings Release (ER) if the announcement is considered the initial announcement of quarterly results. However, the document explicitly states the results will be announced on February 8, 2024, and this document is dated January 31, 2024, so it is a notice of the upcoming earnings release and call, not the release itself. Therefore, it is best classified as Regulatory Filings (RNS) as a general regulatory announcement about the earnings call schedule and results release date, not the earnings release itself.
2024-01-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.